Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.60 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30459997 | 1.00 | IKZF2 (0.64) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| SCHEMBL31077305 | 0.92 | IKZF2 (0.61) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| SCHEMBL25227367 | 0.92 | IKZF2 (0.61) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| SCHEMBL30790518 | 0.92 | IKZF1 (0.65) | IKZF2CRBNIKZF1 | |
| SCHEMBL30458571 | 0.92 | IKZF2 (0.62) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| Trifluoroacetic Acid SCHEMBL31372295 | 0.92 | IKZF2 (0.60) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| SCHEMBL30459793 | 0.91 | IKZF2 (0.65) | IKZF2CRBNIKZF1 | |
| SCHEMBL31077350 | 0.90 | IKZF2 (0.59) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| SCHEMBL25230212 | 0.90 | IKZF2 (0.59) | IKZF2CRBNIKZF1GSPT1DDB1 | |
| SCHEMBL25647442 | 0.90 | IKZF2 (0.56) | IKZF2CRBNIKZF1GSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260014260-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025034789-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK DEGRADERS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023230059-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022268229-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | 和径医药科技（上海）有限公司 | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | IKZF2 4650/4885CRBN 9/4885IKZF1 4063/4885 |
| US-20260014260-A1 | MDM2 DEGRADER | MDM2, TP53, ADRM1 | IKZF2 3360/4885CRBN 29/4885IKZF1 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.